WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2008092887) I-OXA-3-AZASPIRO (4.5) DECAN-2-ONE AND 1-OXA-3, 8-DIAZASPIRO (4.5) DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2008/092887    International Application No.:    PCT/EP2008/051110
Publication Date: 07.08.2008 International Filing Date: 30.01.2008
IPC:
C07D 413/12 (2006.01), C07D 413/14 (2006.01), C07D 417/14 (2006.01), C07D 498/10 (2006.01), A61K 31/423 (2006.01), A61P 3/00 (2006.01), A61P 25/00 (2006.01)
Applicants: GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB) (For All Designated States Except US).
BENTLEY, Jonathan [GB/IT]; (IT) (For US Only).
BIAGETTI, Matteo [IT/IT]; (IT) (For US Only).
CARDULLO, Francesca [IT/IT]; (IT) (For US Only).
GENSKI, Thorsten [DE/IT]; (IT) (For US Only).
KOPF, Silvia Rosalia [AR/IT]; (IT) (For US Only).
LESLIE, Colin Philip [GB/IT]; (IT) (For US Only).
MELOTTO, Sergio [IT/IT]; (IT) (For US Only).
MENICONI, Mirco [IT/IT]; (IT) (For US Only).
MERLO, Giancarlo [IT/IT]; (IT) (For US Only).
PIZZI, Domenica Antonia [IT/IT]; (IT) (For US Only).
SERI, Catia [IT/IT]; (IT) (For US Only)
Inventors: BENTLEY, Jonathan; (IT).
BIAGETTI, Matteo; (IT).
CARDULLO, Francesca; (IT).
GENSKI, Thorsten; (IT).
KOPF, Silvia Rosalia; (IT).
LESLIE, Colin Philip; (IT).
MELOTTO, Sergio; (IT).
MENICONI, Mirco; (IT).
MERLO, Giancarlo; (IT).
PIZZI, Domenica Antonia; (IT).
SERI, Catia; (IT)
Agent: MAURO, Marina; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB)
Priority Data:
0701962.3 01.02.2007 GB
0720880.4 24.10.2007 GB
Title (EN) I-OXA-3-AZASPIRO (4.5) DECAN-2-ONE AND 1-OXA-3, 8-DIAZASPIRO (4.5) DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS
(FR) DÉRIVÉS 1-OXA-3-AZASPIRO [4,5] DÉCANE-2-ONE ET 1-OXA-3,8-DIAZASPIRO [4,5] DÉCANE-2-ONE POUR LE TRAITEMENT DE TROUBLES DE L'ALIMENTATION
Abstract: front page image
(EN)The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, formula (I) wherein R is an aryl or heteroaryl; which may be substituted by one or more: halogen, C1 -C4 alkyl, C1-C4 alkoxy, C1 -C4 haloalkyl, C1 -C4 haloalkoxy, cyano; W is -CZ1 or nitrogen; Z1 is hydrogen, C1 -C4 alkyl; A is a 5 membered heteroaryl, pyrazine, pyrimidine, or quinoline or quinazoline which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1 -C4 haloalkyl, C1 -C4 haloalkoxy, cyano; B is hydrogen or a 5-10 membered aryl or heteroaryl which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1 -C4 haloalkyl, C1 -C4 haloalkoxy, cyano; being A and B linked via any atom; provided that when W is -CZ1, compounds of formula (I) have a trans stereochemistry; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as NPY Y5 receptor antagonists and as agents for the treatment and/or prophylaxis of eating disorders such as a binge eating disorder.
(FR)L'invention concerne de nouveaux composés de formule (I) ou un sel ou un solvate pharmaceutiquement acceptable de ceux-ci, R étant aryle ou hétéroaryle; pouvant être substitué par : halogène, C1-C4-alkyle, C1-C4-alcoxy, C1-C4-haloalkyle, C1-C4-haloalcoxy et/ou cyano; W étant -CZ1 ou azote; Z1 étant hydrogène ou C1-C4-alkyle; A étant hétéroaryle, pyrazine, pyrimidine, quinoléine ou quinazoline à 5 éléments, pouvant être substitué par halogène, C1-C4-alkyle, C1-C4-alkoxy, C1-C4-haloalkyle, C1-C4-haloalkoxy et/ou cyano; B étant hydrogène ou un aryle ou hétéroaryle à 5 éléments pouvant être substitué par : halogène, C1-C4-alkyle, C1-C4-alcoxy, C1-C4-haloalkyle, C1-C4-haloalcoxy et/ou cyano; A et B étant liés par n'importe quel atome; à la condition que lorsque W est -CZ1, les composés de formule (I) ont une stéréochimie trans. L'invention concerne également des procédés de fabrication de ces composés, des intermédiaires employés dans ces procédés, des compositions pharmaceutiques contenant ces composés et leur utilisation en thérapie, en tant qu'antagonistes du récepteur de NPY Y5, et en tant qu'agents pour le traitement et/ou la prophylaxie de troubles de l'alimentation tels que la frénésie alimentaire.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)